Renal denervation (RDN) is facing various challenges to its initial claimed value in hypertension treatment. Major concerns are the choice of the patients and the technical efficacy of the RDN. Different factors have been described as predicting the capacity of RDN to decrease blood pressure. These factors are related to the patients, the procedure and the tools to confirm successful neural ablation. Their use in future trials should help to improve RDN trials understanding and outcomes. This review summarizes the different predictive factors available and their potential benefits in patient selection and in procedure guidance.
Introduction
Renal denervation (RDN) has provided a promising option in hypertension treatment for nearly a decade. However, after the first SYMPLICITY trials [1, 2] , two sham-controlled trials did not reach their primary endpoint [3, 4] , with no significant change in blood pressure level between RDN and sham arms at 6 months. The third one failed to demonstrate an effect on blood pressure in intention to treat [5] . The negative results given by the published sham-controlled studies, built with a robust methodology, could have stopped the development of this technique. On the contrary, the medical community is still very interested for several reasons. First, the sham-controlled studies have major acknowledged limitations [6, 7] . Further, the possible value of RDN could extend beyond the hypertension field, for example to benefits in atrial fibrillation [8, 9] and in reducing heart failure recurrence [10] . Moreover, a major reason seems to be the unexplained dispersion of the BP variation in the studies [11] . Thus, investigators have been encouraged by impressive results in some individuals despite possibly negative results overall.
This problem of dispersion is not easy to solve because we are in front of an equation with two unknown variables. If ongoing sham-controlled studies try to limit bias using ambulatory blood pressure monitoring (ABPM) and by minimizing drug changes during the trial, we still cannot identify the potential 'good responder', and we cannot identify the 'good denervation'. In short, in determining the therapeutic outcome of RDN, there is a fundamental dualism between the preferred hypertension neural pathophysiology and the technical factors producing optimal denervation. The solution could come from application of the predictive factors for successful denervation disclosed in the published studies. We propose a review of these various factors which could help, variously, to correctly select the patient, to guide the denervation procedure, to quantify the achieved denervation and to confirm the benefits of RDN.
Patients
Hypertension is a multifaceted disease with different regulatory systems involved. From the outset, secondary hypertension has been rightly an exclusion criterion for RDN, to avoid treating a hyperaldosteronism or a Cushing syndrome patient with RDN. Similarly, renal arteries imaging used to confirm the feasibility of the denervation procedure is a guarantee to diagnose renal artery stenosis, which also is an exclusion. Certainly, the enthusiasm for RDN has improved the detection of secondary hypertension in patients with resistant hypertension.
In the identification of patients likely to benefit from RDN the SYMPLICITY-3 trial, the first sham-controlled study has provided some pointers [3] . Subgroups analyses were helpful in confirming that young people, those not black and those without impaired renal function were more likely to respond. This is perhaps the composite face of the patient with a high sympathetic nervous system activity, rather than with their hypertension driven by other regulatory systems.
Neural pathophysiology: what form, how to test?
The renal sympathetic nerves strongly influence renin secretion and renal tubular reabsorption of sodium, factors very important in hypertension pathogenesis [12, 13] . The renal sympathetic outflow is commonly activated in essential hypertension and especially in resistant hypertension [14] . Therapeutic targeting of these patients by renal sympathetic denervation is logical, while no specific drug is available to block the sympathetic activation in hypertension. Accurate measurement of sympathetic activity in the kidneys is possible with the isotope dilution technique for determining renal noradrenaline spillover [15] , but this information is not available in the clinical setting. Are any simpler measures of sympathetic activity available which could be substituted, to aid in selecting patients for denervation who have neurogenic hypertension? Simple tests, such as measurement of noradrenaline in urine or plasma, have not been tested as predictors of the RDN BP response, but are unlikely to be sufficiently precise to be helpful. The more accurate test of clinical microneurography, which records sympathetic nerve firing in sympathetic nerves directed to skeletal muscle blood vessels, might be useful as a predictor of RDN response, but has not been tested. Again, this test will not predict sympathetic outflow to the kidney, the key neural pathophysiology.
Prerenal denervation blood pressure
Until recently, patients with drug-resistant hypertension were the only target population. Demonstration of an activated renal sympathetic outflow in resistant hypertension does corroborate the selection of these patients in studies [14] , but the uncertainty of the benefit/risk ratio in the first SYMPLICITY trials was the true reason to target this population [1, 2] . Earlier studies were focused on severe hypertension, with systolic hypertension exceeding 160 mmHg [16] . Greater severity means in general longer history of hypertension and more nonreversible end-organ damages and arterial stiffness, both adding confounding factors to the blood pressure response to RDN. The proven safety shown in the different studies and registries allows widening of the indications for denervation. Ongoing sham-controlled projects reflect this. Patients with BP higher than 140/90 are now being recruited in current trials, and some studies include patients free of treatment (SPYRAL HTN OFF-MED [17] , RADIANCE HTN SOLO (Clinical trials.-gov identifier: NCT02649426)). Studies in untreated patients are probably the best opportunity to limit the confounding effects of variable and uncertain drug adherence; in the otherwise, exemplary French DENERHTN study at least 50% of patients was incompletely drug adherent [18] .
An additional important observation was made by Persu et al. [19] , who differentiated responders according to ambulatory and office BP. Responders according to office BP were more likely to have a white-coat hypertension and no significant change of ambulatory BP after RDN. In contrast, baseline ambulatory BP was a predictor of BP response in ambulatory BP responders. This overestimation of BP response to RDN based on office blood pressure measurements has dictated the mandatory use of ABPM in RDN studies.
Isolated systolic hypertension
In addition to the predenervation level of BP, the type of hypertension seems to be important. Ewen et al. [20] demonstrated a lower BP response to RDN in patients with isolated systolic hypertension (ISH). Similarly, pooled data from both the SYMPLICITY-3 trial and the Global Symplicity Registry demonstrate lower effect of RDN in ISH compared to combined systolic-diastolic hypertension [21] . In ISH, the blood pressure elevation is mediated more by biomechanical factors than neural mechanisms. Indeed, ISH is closely associated with increased pulse wave velocity and wave reflection [22] . These mechanisms lead to a larger pulse pressure and an arterial stiffness increase, two predictors of end-organ damages. Interestingly, in contrast to the first publication of SYMPLI-CITY-3 results, age is no longer a predictive factor when ISH is added to the multivariate model. Okon et al. [23] also demonstrated that higher arterial stiffness, evaluated by invasive pulse wave velocity measurements, was associated with a lower BP response to RDN. ISH and arterial stiffness are predominant in elderly people; however, vascular age might be an additional predictive factor to chronological age, in particular to identify young subjects with a potential altered vascular elasticity.
Current antihypertensive medication
Expert consensus leads to a standardized treatment combining diuretic and renin-angiotensin-aldosterone axis blockade in resistant hypertensive patients [24] . The absence of antiadrenergic drugs currently high on the list of preferred drugs would be expected to increase the chance that patients with resistant hypertension included in RDN studies would have sympathetically mediated hypertension. Various post hoc analyses have shown a relationship between the drug treatment in resistant hypertension and the blood pressure reduction with RDN [7, 21, 25] . This perhaps takes two forms. First, antihypertensive drugs which suppress the sympathetic nervous system, by an additive effect, might act in concert with the denervation, promoting larger BP fall. And second, prescribing of drugs associated with lowest compliance might be noted to be linked to less post-RDN BP effect, as dosing is stopped. The use of a central sympatholytic agent enhances the BP response [25] . Baseline aldosterone antagonists use and lack of vasodilator use at baseline are predictors of the 6-month response [7, 21] . Aldosterone antagonists and vasodilators are known to have a low persistence and compliance. These observations should promote a systematic analysis of plasmatic and/or urinary antihypertensive drug metabolites in RDN studies, testing drug compliance, to confirm the hypothesis of drug-related response [24] .
Obesity and obstructive sleep apnoea
Obesity increases sympathetic activity [26] . The sympathetic activation of obesity-related hypertension differs from that of normal-weight essential hypertension in two important ways, in excluding the cardiac sympathetic outflow and in the singlefibre pattern of sympathetic activation, which involves an increase in the number of fibres firing (by recruitment of previously silent ones), these fibres firing at a normal rate, unlike in normal-weight essential hypertension where nerve firing rate is increased [27] . Obesity-hypertension should be a good substrate for sympathetic RDN, as the renal sympathetic outflow is activated, but the evidence is sparse. In the Greek Registry [23] , higher body mass index (BMI) at baseline was associated with greater BP fall on RDN. But in contrast, some other nonrandomized studies found a better response in patients with lower BMI [28, 29] . In the SYMPLICITY-3 trial, no relation was found between BMI and response, but obstructive sleep apnoea (OSA) patients had greater BP fall with RDN [30] . Conversely, in the Global Symplicity Registry, OSA was not a predictive factor for BP response [31] . To summarize, known neural pathophysiology would predict greater BP fall with RDN in obesity-hypertension and OSA, but the evidence is inconclusive.
Renal function and chronic kidney disease
Two studies suggest that renal function impairment is a predictive factor of RDN failure. In both the SYMPLICITY-3 trial and the European ENCOReD cohort, RDN responders had a higher glomerular filtration rate than nonresponders [19, 32] . This contrasts with the expectation that the neural pathophysiology of chronic kidney disease (CKD), a marked activation of the sympathetic nervous system, should be predictive of RDN success [33] . And several studies without sham control in renal hypertension certainly do show striking BP benefit from RDN, both with moderately reduced glomerular filtration rate [34] [35] [36] and in end-stage renal disease [37] . Patients with renal hypertension constitute a difficult population to study because the mechanisms involved in generating and sustaining the hypertension can be multiple [38] . In CKD, the prevalence of arterial stiffness and end-organ damage is increased, adding confounding factors. Although these patients should not be recruited into trials aiming to confirm the generic efficacy of the RDN technique, this does not exclude the probability that RDN might be recommended for renal hypertension in the future.
Other markers SYMPLICITY-3 trial results suggest that black-skinned people have lower RDN response rates than Caucasians [3, 7] .
Although it has been suggested that this might be explained by salt-sensitive hypertension in black people [39] , differentiating biological correlates of ethnicity, such as this, from behavioural and socioeconomic determinants, particularly those related to drug adherence, has to-date not been possible.
Other baseline markers have been noted to predict the effect of RDN on BP. For example, low serum level of vitamin D was described as predicting a lower response to RDN [40] . A mechanism to explain this is lacking. Perhaps not surprising, various aspects of renal artery anatomy has been shown to influence the BP response [41] . For example, better results were obtained in those patients having a single renal artery passing to both kidneys. All these results are post hoc analyses and deserve more investigations.
Procedure
A variety of technical issues appear to predict the BP response to RDN.
Operator training and number of ablation points
Gone are the days when RDN was poised to enter every cardiac catheter laboratory. There is more and more evidence that success depends on the experience and training of the operator. RDN is not 'easy'. The SYMPLICITY-3 trial proved this point [5] . In this trial, 31% of the procedures were the first and only one carried out by the operator, and more than 50% of the operators conducted at most two procedures, without previous 'hands-on' training. Directly linked to the inexperience of the operators, 74% of simplicity-3 patients did not receive a circumferential ablation even for one renal artery, when the protocol dictated this be carried out bilaterally. It means that very few patients were subjected to a complete denervation [20] .
The number of ablations in the SYMPLICITY-3 trial was associated with the BP response, a significant decrease of BP being obtained with more than 12 ablations points. Similarly, in the Danish sham-controlled study, the number of 'successful' ablations, defined in terms of a satisfactory procedure, was 5Á5 on average in each renal artery [4] . This is better procedural performance than in many previous studies but insufficient to ensure a circumferential neural ablation. An approximately analogous situation occurs with the presence of an accessory renal artery which has not been ablated; persistence of sympathetic communication from inadequate denervation can cause RDN failure [42] . energy towards the neural targets. Energy flow can be deflected by lymph nodes and skeletal muscle, while veins can act as an energy 'sinks' [44] . As with sympathetic nerves, these peripheral structures cannot be visualized at angiography. This anatomical distortion of energy flow doubtless reduces the efficacy and predictability of the RDN procedure.
New insights about renal anatomy
In the first studies, ablative RF energy was delivered near the ostium of renal arteries, based on a hypothetical improvement of efficacy/safety balance. But this decision to deliver energy proximally was based on a misinterpretation. There are two categories of sympathetic nerves surrounding the renal arteries: nerves actually innervating the artery and nerves of passage destined for the kidneys requiring ablation. The total number of periarterial sympathetic nerves does fall moving distally, but this is entirely due to the nerves to the arterial wall dropping out. Ostial energy delivery was devised also to minimize direct and unwanted energy delivery to the kidneys.
Importantly, anatomical and histological studies later demonstrated that nerves are closer to the lumen in the distal part of the renal arteries, and the renal artery divisions, where they are more readily reached by delivered energy [45] [46] [47] . Recent studies have also shown that innervation was more important in the medial and the distal part of the renal artery, where the number of sympathetic fibres is higher [48, 49] . Furthermore, contradictory results are found about the predominant repartition of the fibres around the artery in the different studies [45, 47, 49] . Fibres are perhaps statistically less represented in the dorsal region, but this is important to remember they are disseminated all around the artery. This emphasizes the need to achieve a circular ablation to ensure a better result.
Supporting these findings, a recent randomized single-centre study compared distal versus proximal denervation in 51 hypertensive subjects; distal energy delivery lowered blood pressure more [50] . Interestingly, even though the study protocol was not of sham design, the authors were able to keep both investigators and patients blinded to the therapy, limiting bias and in particular the Hawthorne effect. In an experimental porcine model, similar results were obtained [51] . These results were not confirmed in a single human study which compared BP-lowering efficacy between proximal and full-length artery energy delivery [52] . There are technical limitations with this study; the primary endpoint was office blood pressure and the mean number of ablations was only 6 and 3 in each artery for full-length and proximal denervation, respectively. Ongoing sham trials are now aware of this issue (SPYRAL HTN [17] , AUSHAM RDN-01 (clinicaltrials.gov identifier: NCT02444442)).
Maintain the safety
Could more intensive ablation efforts perhaps decrease procedural safety? This problem will be assessed in future studies. The prevalence of renal artery stenosis after RDN clearly is very low, but there is some evidence that this differs according to the device used for RDN. Further, stenosis appears to be more frequent if RF energy is delivered in the presence of existing mild renal artery stenosis, but also has been rarely described de novo with previously normal renal arteries [53] . Moreover, following the now adopted procedure of treating the distal part of the vessel and renal artery divisions, the risk of stenosis perhaps might increase [54] . However, it is appropriate to emphasize that the incidence of stenosis does remain low both in registries and in trials designed to systematically assess the occurrence of renal stenosis [55] .
New devices
The level of RDN experience clearly favours radiofrequencybased RDN, with relatively few studies being carried out with other devices in human. Until recently, all RDN results were derived from the first generation unipolar catheters [56, 57] . New registries are producing data based on multipolar catheters, which have the benefits of significant reduction in procedural duration, and delivery of a more standardized ablation. Even though unipolar and multipolar devices have not been directly compared in humans, from experimental studies and the clinical failures with unipolar devices in the past, we can anticipate the benefit of these new devices.
It is possible that other devices may be able to improve the overall benefit of RDN, beyond that achieved with RF energy delivery. The most developed alternatives are based on intraluminal ultrasound technology [58] and chemical neurolysis [59] . More human studies will be needed, but the claimed preclinical benefits are less damage to the intima-media layer of the renal arteries and more efficient ablation of sympathetic nerves.
In conclusion, RDN is definitely not as easy as it looks. New devices should help to achieve more complete denervation. But the technique must stay in the hands of trained operators, in centres with a high volume of procedures. In addition, applying an increased number of ablation points may be a necessary 'insurance policy' as, without availability of definitive testing for achieved ablation we currently cannot be sure that the denervation is effective.
Achieved denervation
There is a critical need for indices of a successful RDN. The testing would be one of two types: (i) chronic (post hoc) testing of renal sympathetic denervation, which might aid in the interpretation of RDN results, but would not be available to guide the operator on the procedural day, (ii) acute testing, which potentially could guide the operator.
Chronic or post hoc markers
By definition, chronic markers are in fact not predictive, but interpretive. Indeed, they will not help to immediately confirm the technical success of the RDN but they are, however, important to explain the effects of RDN and particularly to confirm the link between BP drop and RDN. Definitive clinical evidence of efferent sympathetic nerve ablation is provided by renal noradrenaline spillover measurements [11] . This method, although valid, has very limited availability. Clinical microneurography, measuring the sympathetic outflow to the skeletal muscle vasculature (MSNA), detects afferent renal ablation and consequent inhibition of CNS sympathetic outflow [60] . Various additional markers have been described as being associated with the RDN BP response. In general, they are markers of end-organ damage such as that involving endothelial function [61, 62] , arterial stiffness [33, 63, 64] , heart failure [36] , inflammation, cardiac remodelling [65] or insulin resistance [66] . Unfortunately, among these different markers, none have been demonstrated in sham-controlled trials and the number of subjects involved is low. Therefore, there is insufficient evidence to confirm their validity as yet.
Acute or intraprocedural markers
Finding a reproducible marker of sympathetic nerve lysis would help in the documentation of denervation. There is a need to find a hemodynamic response, or perhaps, a serum or urine biomarker to judge early if the denervation should be repeated, on the procedural day, or soon after. In one study, a decrease in renal veno-arterial noradrenaline gradient immediately after RDN was seen in BP responders, providing information similar to noradrenaline spillover measurements, although less precise [67] . In an experimental study, renalase, a renal enzyme possibly involved in noradrenaline degradation, was increased 1 week after surgical denervation [68] . This observation, of uncertain significance, needs confirmation in human studies. D€ orr et al. [69] , were the first to identify an acute marker of RDN in humans. They found that brainderived neurotrophic factor serum levels were decreased 2 h after denervation in RDN BP responders. The pathway of those changes is not clear. Identifying in urine or plasma released components of sympathetic axons, the products of neuronal lysis, would be a concept easier to explain. Following that hypothesis, we found that the increase in the arterial plasma concentration of chromogranin A, a sympathetic nerve vesicular protein, could predict the change of diastolic blood pressure post-RDN [70] . In detail, the acute change of chromogranin A concentrations was correlated with the diastolic BP change at 3 months. Further studies are needed to confirm these results.
Blood pressure recording associated with electrical renal nerve stimulation (RNS) on the procedural day is also a path to investigate. RNS elevates blood pressure by stimulating centrally directed renal afferent nerves. Effective ablation of afferent nerves will abolish this evoked affect. Chinushi et al. [71] , in a dog model, have shown that RNS allowed immediate verification of the efficacy of the RDN procedure. Gal et al. [72] , in human, showed efficient denervation inhibited of the evoked RNS pressor response. Applying this mechanistic approach, de Jong et al. [73] , recently showed that procedural RNS change predicts ABPM fall at 3-6 months.
To summarize, various markers have potential interest for confirming the efficacy of the RDN technique. In addition to post hoc predictive markers, acute marker development is critical to help the operator assess the efficiency of the intervention. The most promising marker seems to be RNS but whether this technique could be widely adopted is problematic. Renal nerve stimulation is painful, and the human studies carried out by Gal et al. and de Jong et al., were performed with general anaesthesia [72, 73] .
Conclusion
Renal denervation is a more challenging technique than expected initially. The selective recruitment of hypertensive patients who will respond well, with a clinically helpful blood pressure fall remains complex. Some predictive factors have been identified but thresholds are definitely not so easy to set, to determine which patients could benefit from the technique. Currently, the identification of responders is moreover complicated by the uncertain, undocumented success of the denervation procedure. However, some markers could help to confirm successful denervation.
In the light of the negative results from the previous shamcontrolled studies, predictive markers are needed (i) to confirm or rebut the efficacy of the technic and (ii) to help the physician to assess the technical success of the denervation. The confirmation of existing markers and development of new ones are critical to determine the place of RDN in the overall therapeutic scheme of hypertension.
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